Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects - PubMed (original) (raw)

Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects

P Patrignani et al. J Clin Invest. 1982 Jun.

Abstract

Acetylation of platelet cyclooxygenase by oral aspirin is dose dependent and cumulative with repeated administration. However, no single dose of aspirin has been found to be completely selective of platelet thromboxane (TX) synthesis inhibition in man. We determined the dose dependence, cumulative nature and selectivity of aspirin effects on platelet TXB(2) and renal prostaglandin (PG) and prostacyclin (PGI(2)) production. We measured, by radioimmunoassay, serum TXB(2) levels after whole blood clotting and urinary excretion of PGE(2), PGF(2alpha), and 6-keto-PGF(1alpha), before and after single or repeated oral aspirin doses given to 46 healthy subjects. Single doses of 6-100 mg aspirin resulted in a linear (r = 0.92, P < 0.01) inhibition of platelet TXB(2) production, ranging from 12 to 95% after 24 h. A daily dose of 0.45 mg/kg given for 7 d produced a cumulative and virtually complete inhibition of platelet TXB(2) production, without significantly reducing the urinary excretion of PGE(2), PGF(2alpha), and 6-keto-PGF(1alpha) in both healthy men and women. The platelet inhibitory effect of this regimen was maintained unaltered throughout 1 mo of therapy, with no evidence of cumulative inhibition of renal PG-synthesis. Moreover, furosemide-induced renal PGI(2) synthesis and renin release were unaffected by chronic low-dose aspirin. Following cessation of aspirin therapy, platelet TXB(2) production returned toward control values at a similar rate as after a single higher dose. WE CONCLUDE THAT IN HEALTHY SUBJECTS: (a) aspirin causes a dose-dependent inhibition of platelet TXA(2) production, with no obvious sex-related difference; (b) the inhibitory effect of daily low-dose aspirin is cumulative on platelet TXA(2) but not on renal PG-synthesis; (c) during chronic low-dose aspirin therapy, renal PGI(2)-producing cells are readily activable by furosemide at a time of virtually complete suppression of platelet cyclooxygenase activity.

PubMed Disclaimer

Similar articles

• Reduced platelet thromboxane formation in uremia. Evidence for a functional cyclooxygenase defect.
  Remuzzi G, Benigni A, Dodesini P, Schieppati A, Livio M, De Gaetano G, Day SS, Smith WL, Pinca E, Patrignani P, Patrono C. Remuzzi G, et al. J Clin Invest. 1983 Mar;71(3):762-8. doi: 10.1172/jci110824. J Clin Invest. 1983. PMID: 6298281 Free PMC article.
• Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man.
  FitzGerald GA, Oates JA, Hawiger J, Maas RL, Roberts LJ 2nd, Lawson JA, Brash AR. FitzGerald GA, et al. J Clin Invest. 1983 Mar;71(3):676-88. doi: 10.1172/jci110814. J Clin Invest. 1983. PMID: 6338043 Free PMC article.
• Synthesis of prostacyclin from platelet-derived endoperoxides by cultured human endothelial cells.
  Marcus AJ, Weksler BB, Jaffe EA, Broekman MJ. Marcus AJ, et al. J Clin Invest. 1980 Nov;66(5):979-86. doi: 10.1172/JCI109967. J Clin Invest. 1980. PMID: 6776148 Free PMC article.
• Clinical pharmacology of platelet cyclooxygenase inhibition.
  Patrono C, Ciabattoni G, Patrignani P, Pugliese F, Filabozzi P, Catella F, Davì G, Forni L. Patrono C, et al. Circulation. 1985 Dec;72(6):1177-84. doi: 10.1161/01.cir.72.6.1177. Circulation. 1985. PMID: 3933848 Review.
• Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects.
  Capone ML, Sciulli MG, Tacconelli S, Grana M, Ricciotti E, Renda G, Di Gregorio P, Merciaro G, Patrignani P. Capone ML, et al. J Am Coll Cardiol. 2005 Apr 19;45(8):1295-301. doi: 10.1016/j.jacc.2005.01.045. J Am Coll Cardiol. 2005. PMID: 15837265 Review.

Cited by

• Aspirin in Primary Prevention: Looking for Those Who Enjoy It.
  Della Bona R, Giubilato S, Palmieri M, Benenati S, Rossini R, Di Fusco SA, Novarese F, Mascia G, Gasparetto N, Di Monaco A, Gatto L, Zilio F, Sorini Dini C, Borrello F, Geraci G, Riccio C, De Luca L, Colivicchi F, Grimaldi M, Giulizia MM, Porto I, Oliva FG. Della Bona R, et al. J Clin Med. 2024 Jul 16;13(14):4148. doi: 10.3390/jcm13144148. J Clin Med. 2024. PMID: 39064188 Free PMC article. Review.
• Optimizing the use of aspirin for cardiovascular prevention.
  Casado-Arroyo R, Sostres C, Lanas A. Casado-Arroyo R, et al. Drugs. 2013 Jun;73(8):803-14. doi: 10.1007/s40265-013-0061-z. Drugs. 2013. PMID: 23677803 Review.
• Inhibition by picotamide of thromboxane production in vitro and ex vivo.
  Violi F, Ghiselli A, Iuliano L, Praticò D, Alessandri C, Balsano F. Violi F, et al. Eur J Clin Pharmacol. 1988;33(6):599-602. doi: 10.1007/BF00542494. Eur J Clin Pharmacol. 1988. PMID: 3366163
• Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: A consensus-based position paper.
  Barbui T, De Stefano V, Falanga A, Finazzi G, Martinelli I, Rodeghiero F, Vannucchi AM, Barosi G. Barbui T, et al. Blood Cancer J. 2019 Aug 8;9(8):61. doi: 10.1038/s41408-019-0225-5. Blood Cancer J. 2019. PMID: 31395856 Free PMC article.

References

1. 1. J Clin Endocrinol Metab. 1969 Oct;29(10):1349-55 - PubMed
2. 1. J Clin Invest. 1975 Apr;55(4):763-70 - PubMed
3. 1. Proc Natl Acad Sci U S A. 1975 Aug;72(8):3073-6 - PubMed
4. 1. N Engl J Med. 1977 Dec 8;297(23):1246-9 - PubMed
5. 1. J Clin Invest. 1978 Feb;61(2):314-9 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • American Society for Clinical Investigation
  • Europe PubMed Central
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations Database